Renal Toxicity with Sevoflurane: A Storm in a Teacup?

Gentz, B.A.; Malan, T.P.J.
December 2001
Drugs;Dec2001, Vol. 61 Issue 15, p2155
Academic Journal
The inhaled anaesthetic sevoflurane is metabolised into two products that have the potential to produce renal injury. Fluoride ions are produced by oxidative defluorination of sevoflurane by the cytochrome P450 system in the liver. Until recently, inorganic fluoride has been thought to be the aetiological agent responsible for fluorinated anaesthetic nephrotoxicity, with a toxic concentration threshold of 50 μmol/L in serum. However, studies of sevoflurane administration in animals and humans have not shown evidence of fluoride-induced nephrotoxicity, despite serum fluoride concentrations in this range. Compound A (fluoromethyl-2,2-difluoro-1-[trifluoromethyl] vinyl ether) is a breakdown product of sevoflurane produced by its interaction with carbon dioxide absorbents in the anaesthesia machine. The patient then inhales compound A. Compound A produces evidence of transient renal injury in rats. The mechanism of compound A renal toxicity is controversial, with the debate focused on the role of the renal cysteine conjugate β-lyase pathway in the biotransformation of compound A. The significance of this debate centres on the fact that the β-lyase pathway is 10- to 30-fold less active in humans than in rats. Therefore, if biotransformation by this pathway is responsible for the production of nephrotoxic metabolites of compound A, humans may be less susceptible to compound A renal toxicity than are rats. In three studies in human volunteers and one in surgical patients, prolonged (8-hour) sevoflurane exposures and low fresh gas flow rates resulted in significant exposures to compound A. Transient abnormalities were found in biochemical markers of renal injury measured in urine. These studies suggested that sevoflurane can result in renal toxicity, mediated by compound A, under specific circumstances. However, other studies using prolonged sevoflurane administration at low flow rates did not find evidence of renal injury. Finally, there are substantial data to document the safety of sevoflurane administered for shorter durations or at higher fresh gas flow rates. Therefore, the United States Food and Drug Administration recommends the use of sevoflurane with fresh gas flow rates at least 1 L/min for exposures up to 1 hour and at least 2 L/min for exposures greater than 1 hour. We believe this is a rational, cautious approach based on available data. However, it is important to note that other countries have not recommended such limitations on the clinical use of sevoflurane and problems have not been noted.


Related Articles

  • Biological monitoring of kidney function among workers occupationally exposed to trichloroethylene. Green, T.; Dow, J.; Ong, C. N.; Ng, V.; Ong, H. Y.; Zhuang, Z. X.; Yang, X. F.; Bloemen, L. // Occupational & Environmental Medicine;Apr2004, Vol. 61 Issue 4, p312 

    Aims: To investigate the nephrotoxic potential of trichloroethylene in a currently exposed population using sensitive urinary markers of kidney toxicity. Methods: Renal dysfunction was monitored in a cross-sectional study of 70 workers currently exposed to trichloroethylene. An age and sex...

  • Nephrotoxicity Testing in Vitro - What We Know and What We Need to Know. Pfaller, Walter; Gstraunthaler, Gerhard // Environmental Health Perspectives Supplements;Apr98 Supplement 2, Vol. 106, p559 

    Discusses the use of in vitro techniques using isolated renal cells, nephron fragments, or cell cultures derived from specific renal cell types to improve insight into the molecular mechanisms involved in nephrotoxicity.

  • Methoxyflurane nephropathy Mazze, Richard I. // Environmental Health Perspectives;Jun1976, Vol. 15, p111 

    No abstract available.

  • Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Bodei, Lisa; Cremonesi, Marta; Ferrari, Mahila; Pacifici, Monica; Grana, Chiara; Bartolomei, Mirco; Baio, Silvia; Sansovini, Maddalena; Paganelli, Giovanni // European Journal of Nuclear Medicine & Molecular Imaging;Oct2008, Vol. 35 Issue 10, p1928 

    A correction to the article "Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors" that was published in the August 9, 2008 issue is presented.

  • Tenofovir-disoproxil-fumarate: Renal toxicity: case report.  // Reactions Weekly;6/22/2019, Vol. 1758 Issue 1, p331 

    No abstract available.

  • Urinary α1-microglobulin excretion as biomarker of renal toxicity in trichloroethylene-exposed persons. Bolt, Hermann M.; Lammert, Magda; Selinski, Silvia; Brüning, Thomas // International Archives of Occupational & Environmental Health;Mar2004, Vol. 77 Issue 3, p186 

    Objectives. Concern on human renal toxicity and carcinogenicity of trichloroethylene is based on findings of increased incidences of renal cell cancers in persons with long-lasting and high occupational exposures to this solvent. The full tumour development is likely to require promotional...

  • How anesthetics help.  // Current Health 1;Feb1992, Vol. 15 Issue 6, p20 

    Explains how local and general anesthetics work to block or reduce pain. How pain signals travel to the brain; Ether; Doctors' concern about safety when using general anesthetics.

  • Ether day. Hull, W.W. // Cricket;Mar1990, Vol. 17 Issue 7, p28 

    Describes how ether was discovered. Early methods of putting patients to sleep; Samuel Colt and nitrous oxide; Dr. Crawford Williamson Long and ether; Dr. William T.G. Morton and Dr. John Collins Warren use ether in surgery on October 16, 1846; October 16 was then declared `Ether Day.'

  • New anesthetic cream for children.  // Child Health Alert;Apr94, Vol. 12, p3 

    Answers a reader's question about an anesthetic cream to prevent the pain from injections that children receive. Eutetic mixture of local anesthetic (EMLA) cream as name; Use in hospitals; Application; Limitations.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics